Scribe Therapeutics completed an upsized IPO targeting $129 million in gross proceeds, positioning the CRISPR-founded company to advance its in vivo gene-silencing pipeline beyond rare disease into earlier cardiometabolic markets. The company priced at $15 per share and will trade on Nasdaq under the ticker SCTX. Scribe’s lead program, STX-1150, is designed to repress the PCSK9 gene—an established cholesterol target already inhibited by approved therapies such as Amgen’s Repatha and Novartis’ Leqvio. A Phase 1 study launched in Australia is enrolling patients with elevated cholesterol and increased atherosclerotic cardiovascular disease risk, with topline data expected in the first half of 2027. The company also earmarked IPO proceeds to push STX-1400 (APOC3) into clinical development and to advance STX-1200 (LPA), both aimed at atherosclerotic cardiovascular disease. The offering came with additional underwriter option value, lifting expected proceeds versus initial expectations. Overall, the IPO reinforces investor focus on platform-scale genetic medicines and the translation of gene editing into broader, high-volume indications with clear biomarker readouts and competitive market landscapes.